| Brittany E Barker, DO | |
|
1701 Innovation Dr, York, PA 17408-8815 | |
| (717) 843-8623 | |
| (717) 815-2489 |
| Full Name | Brittany E Barker |
|---|---|
| Gender | Female |
| Speciality | Family Medicine |
| Location | 1701 Innovation Dr, York, Pennsylvania |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1134414907 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | OT013968 (Pennsylvania) | Secondary |
| 207Q00000X | Family Medicine | OS016385 (Pennsylvania) | Primary |
| Entity Name | Upmc Altoona |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1487604179 PECOS PAC ID: 8426962465 Enrollment ID: O20040406001053 |
News Archive
Synergy Pharmaceuticals, Inc., a developer of new drugs to treat gastrointestinal disorders and diseases, announced today that on February 1, 2011 the U.S. Patent and Trademark Office issued U.S. Patent No. 7,879,802, covering Synergy's novel drug candidate SP-333 to treat inflammatory bowel disease.
If you're one of the nearly half a million Americans living with multiple sclerosis (MS) - a slowly disabling disease of the central nervous system - you are likely dependent on disease-modifying drugs to prevent symptoms such as vision problems, balance issues and weakness. Often, these treatments have been developed through pharmaceutical industry-sponsored clinical trials (ISCT) in collaboration with academic or private practice physicians who care for MS patients.
Chemicals in pharmaceutical drugs can obviously save lives. But as more and stronger chemicals have been introduced, our basic knowledge of the broader health impact of all these chemicals has not kept up with the rapid pace of innovation. There is exceptionally little information on how chemicals in our drugs and also in the environment around us, including on the food we eat, impact some of the most important cells in our body: stem cells. Without basic knowledge and tests on the impact of chemicals on our stem cells, we may be unwittingly damaging essential regenerative functions in our body.
The chairs of the House and Senate Veterans' Affairs committees are pushing for legislation that would allow Congress to approve funding for veterans' health care programs one year in advance, the New York Times reports.
› Verified 2 days ago
| Entity Name | Upmc Altoona |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1437100765 PECOS PAC ID: 8426962465 Enrollment ID: O20040406001118 |
News Archive
Synergy Pharmaceuticals, Inc., a developer of new drugs to treat gastrointestinal disorders and diseases, announced today that on February 1, 2011 the U.S. Patent and Trademark Office issued U.S. Patent No. 7,879,802, covering Synergy's novel drug candidate SP-333 to treat inflammatory bowel disease.
If you're one of the nearly half a million Americans living with multiple sclerosis (MS) - a slowly disabling disease of the central nervous system - you are likely dependent on disease-modifying drugs to prevent symptoms such as vision problems, balance issues and weakness. Often, these treatments have been developed through pharmaceutical industry-sponsored clinical trials (ISCT) in collaboration with academic or private practice physicians who care for MS patients.
Chemicals in pharmaceutical drugs can obviously save lives. But as more and stronger chemicals have been introduced, our basic knowledge of the broader health impact of all these chemicals has not kept up with the rapid pace of innovation. There is exceptionally little information on how chemicals in our drugs and also in the environment around us, including on the food we eat, impact some of the most important cells in our body: stem cells. Without basic knowledge and tests on the impact of chemicals on our stem cells, we may be unwittingly damaging essential regenerative functions in our body.
The chairs of the House and Senate Veterans' Affairs committees are pushing for legislation that would allow Congress to approve funding for veterans' health care programs one year in advance, the New York Times reports.
› Verified 2 days ago
| Entity Name | Pinnacle Health Medical Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1932143427 PECOS PAC ID: 7618960493 Enrollment ID: O20040407000180 |
News Archive
Synergy Pharmaceuticals, Inc., a developer of new drugs to treat gastrointestinal disorders and diseases, announced today that on February 1, 2011 the U.S. Patent and Trademark Office issued U.S. Patent No. 7,879,802, covering Synergy's novel drug candidate SP-333 to treat inflammatory bowel disease.
If you're one of the nearly half a million Americans living with multiple sclerosis (MS) - a slowly disabling disease of the central nervous system - you are likely dependent on disease-modifying drugs to prevent symptoms such as vision problems, balance issues and weakness. Often, these treatments have been developed through pharmaceutical industry-sponsored clinical trials (ISCT) in collaboration with academic or private practice physicians who care for MS patients.
Chemicals in pharmaceutical drugs can obviously save lives. But as more and stronger chemicals have been introduced, our basic knowledge of the broader health impact of all these chemicals has not kept up with the rapid pace of innovation. There is exceptionally little information on how chemicals in our drugs and also in the environment around us, including on the food we eat, impact some of the most important cells in our body: stem cells. Without basic knowledge and tests on the impact of chemicals on our stem cells, we may be unwittingly damaging essential regenerative functions in our body.
The chairs of the House and Senate Veterans' Affairs committees are pushing for legislation that would allow Congress to approve funding for veterans' health care programs one year in advance, the New York Times reports.
› Verified 2 days ago
| Entity Name | Pinnacle Health Hospitalist Services Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023458148 PECOS PAC ID: 9739313545 Enrollment ID: O20131010001079 |
News Archive
Synergy Pharmaceuticals, Inc., a developer of new drugs to treat gastrointestinal disorders and diseases, announced today that on February 1, 2011 the U.S. Patent and Trademark Office issued U.S. Patent No. 7,879,802, covering Synergy's novel drug candidate SP-333 to treat inflammatory bowel disease.
If you're one of the nearly half a million Americans living with multiple sclerosis (MS) - a slowly disabling disease of the central nervous system - you are likely dependent on disease-modifying drugs to prevent symptoms such as vision problems, balance issues and weakness. Often, these treatments have been developed through pharmaceutical industry-sponsored clinical trials (ISCT) in collaboration with academic or private practice physicians who care for MS patients.
Chemicals in pharmaceutical drugs can obviously save lives. But as more and stronger chemicals have been introduced, our basic knowledge of the broader health impact of all these chemicals has not kept up with the rapid pace of innovation. There is exceptionally little information on how chemicals in our drugs and also in the environment around us, including on the food we eat, impact some of the most important cells in our body: stem cells. Without basic knowledge and tests on the impact of chemicals on our stem cells, we may be unwittingly damaging essential regenerative functions in our body.
The chairs of the House and Senate Veterans' Affairs committees are pushing for legislation that would allow Congress to approve funding for veterans' health care programs one year in advance, the New York Times reports.
› Verified 2 days ago
| Entity Name | Pinnacle Health Regional Physicians |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1013441690 PECOS PAC ID: 7416228358 Enrollment ID: O20170810001731 |
News Archive
Synergy Pharmaceuticals, Inc., a developer of new drugs to treat gastrointestinal disorders and diseases, announced today that on February 1, 2011 the U.S. Patent and Trademark Office issued U.S. Patent No. 7,879,802, covering Synergy's novel drug candidate SP-333 to treat inflammatory bowel disease.
If you're one of the nearly half a million Americans living with multiple sclerosis (MS) - a slowly disabling disease of the central nervous system - you are likely dependent on disease-modifying drugs to prevent symptoms such as vision problems, balance issues and weakness. Often, these treatments have been developed through pharmaceutical industry-sponsored clinical trials (ISCT) in collaboration with academic or private practice physicians who care for MS patients.
Chemicals in pharmaceutical drugs can obviously save lives. But as more and stronger chemicals have been introduced, our basic knowledge of the broader health impact of all these chemicals has not kept up with the rapid pace of innovation. There is exceptionally little information on how chemicals in our drugs and also in the environment around us, including on the food we eat, impact some of the most important cells in our body: stem cells. Without basic knowledge and tests on the impact of chemicals on our stem cells, we may be unwittingly damaging essential regenerative functions in our body.
The chairs of the House and Senate Veterans' Affairs committees are pushing for legislation that would allow Congress to approve funding for veterans' health care programs one year in advance, the New York Times reports.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Brittany E Barker, DO 1701 Innovation Dr, York, PA 17408-8815 Ph: () - | Brittany E Barker, DO 1701 Innovation Dr, York, PA 17408-8815 Ph: (717) 843-8623 |
News Archive
Synergy Pharmaceuticals, Inc., a developer of new drugs to treat gastrointestinal disorders and diseases, announced today that on February 1, 2011 the U.S. Patent and Trademark Office issued U.S. Patent No. 7,879,802, covering Synergy's novel drug candidate SP-333 to treat inflammatory bowel disease.
If you're one of the nearly half a million Americans living with multiple sclerosis (MS) - a slowly disabling disease of the central nervous system - you are likely dependent on disease-modifying drugs to prevent symptoms such as vision problems, balance issues and weakness. Often, these treatments have been developed through pharmaceutical industry-sponsored clinical trials (ISCT) in collaboration with academic or private practice physicians who care for MS patients.
Chemicals in pharmaceutical drugs can obviously save lives. But as more and stronger chemicals have been introduced, our basic knowledge of the broader health impact of all these chemicals has not kept up with the rapid pace of innovation. There is exceptionally little information on how chemicals in our drugs and also in the environment around us, including on the food we eat, impact some of the most important cells in our body: stem cells. Without basic knowledge and tests on the impact of chemicals on our stem cells, we may be unwittingly damaging essential regenerative functions in our body.
The chairs of the House and Senate Veterans' Affairs committees are pushing for legislation that would allow Congress to approve funding for veterans' health care programs one year in advance, the New York Times reports.
› Verified 2 days ago
Dr. Sahil Jain, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 1001 S George St, York Hospital, York, PA 17403 Phone: 717-851-2521 | |
Dr. Robert John Pizziketti, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 810 Bonneview Rd, York, PA 17402 Phone: 717-852-7766 Fax: 717-852-7862 | |
Dr. Michael A Wilson, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 4222 Lincoln Hwy, York, PA 17406 Phone: 717-812-2050 Fax: 717-812-2052 | |
Barry A Rott, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1001 S George St, York Hospital, York, PA 17403 Phone: 717-851-2521 Fax: 717-851-3535 | |
Asceline So Go, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 116 S George St, Suite 200, York, PA 17401 Phone: 717-845-8617 Fax: 717-854-6645 | |
Dr. Cathy P. Carpenter, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 80 Wyntre Brooke Dr, York, PA 17403 Phone: 717-741-9462 Fax: 717-741-4399 | |
Patrick Michael Sterling, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2251 Eastern Blvd, York, PA 17402 Phone: 717-840-2730 |